SAN
DIEGO, Aug. 3, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc.® (NASDAQ: MRTX), a commercial
stage biotechnology company, today announced that the company
granted equity awards to a new employee with a grant date of
August 1, 2023, as equity inducement
awards outside of the company's 2022 Equity Incentive Plan (but
under the terms of the company's Inducement Plan) and material to
the employee's acceptance of employment with the company. The
equity awards were approved in accordance with Nasdaq Listing Rule
5635(c)(4).
The employee received options to purchase 5,189 shares of
Mirati's common stock and 3,067 restricted stock units ("RSUs").
The options have an exercise price of $30.02 per share, which is equal to the closing
price of Mirati's common stock on August 1,
2023, (the "Grant Date"). One-fourth of the shares
underlying the employee options will vest on the one-year
anniversary of the Grant Date and thereafter 1/48th of the shares
underlying the employee options will vest monthly, such that the
shares underlying the options granted to the employee will be fully
vested on the fourth anniversary of the Grant Date, subject to the
employee's continued employment with Mirati on such vesting dates.
Each RSU will vest as to 25% of the shares underlying the RSU award
on the first anniversary of the Grant Date and as to an additional
25% of the shares underlying the RSU award annually thereafter,
subject to the employee's continued employment on each vesting
date.
About Mirati Therapeutics, Inc.®
Mirati Therapeutics, Inc. is a commercial stage biotechnology
company whose mission is to discover, design and deliver
breakthrough therapies to transform the lives of patients with
cancer and their loved ones. The company is relentlessly focused on
bringing forward therapies that address areas of high unmet need,
including lung cancer, and advancing a pipeline of novel
therapeutics targeting the genetic and immunological drivers of
cancer. Unified for patients, Mirati's vision is to unlock the
science behind the promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us on Twitter, LinkedIn, and
Facebook.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-301893105.html
SOURCE Mirati Therapeutics, Inc.